Sanofi, Re­gen­eron’s Dupix­ent scores an­oth­er in­di­ca­tion with first-ever ap­proval for nodu­lar skin dis­or­der

Sanofi chief ex­ec­u­tive Paul Hud­son told in­vestors ear­li­er this year that the Big Phar­ma was go­ing to em­pha­size its sales king­pin Dupix­ent mov­ing for­ward. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER